Skinlight cream, 100 mcg+60 me/g 15 g

Glucocorticosteroid combined for topical use

Mometasone furoate is a glucocorticosteroid for topical use.

It has anti-inflammatory, anti-allergic, antipruritic and anti-exudative effects. Inhibits release of inflammatory mediators.

It increases production of lipokortin which is an inhibitor of phospholipase A2, which causes inhibition of release of arachidonic acid.

Prevents marginal accumulation of neutrophils, which reduces inflammatory exudate and cytokine production, inhibits macrophage migration and leads to a decrease in infiltration and granulation processes.

It reduces inflammation due to decrease in formation of chemotaxis substance (effect on “late” allergic reactions) and inhibits development of “immediate” allergic reaction (due to inhibition of production of arachidonic acid metabolites and decrease in release of inflammatory mediators from mast cells).

Heparin is a direct-acting anticoagulant, has anti-inflammatory, antiproliferative, anti-edema and analgesic effects. Reduces platelet aggregation, binds antithrombin III, preventing the transition of prothrombin to thrombin. Inhibits the activity of thrombin.

Decreases the activity of hyaluronidase, increases the fibrinolytic properties of the blood.

Heparin improves microcirculation and activates tissue exchange, due to this accelerates the process of resorption of hematomas and thromboses, eventually restores venous patency, clinically it is accompanied by a pronounced analgesic and anti-inflammatory action.

The absorption of the cream is low. After 8 hours after application on intact skin (without the occlusive dressing) 0.4% of mometasone is detected in the systemic blood flow.

A small amount of heparin is absorbed from the surface of the skin into the systemic blood stream. The maximum concentration of heparin in the blood is observed 8 hours after application.

The excretion of heparin mainly occurs through the kidneys, the elimination half-life is 12 hours.

.

Indications

Dermatological diseases (including. Chronic skin conditions (including chronic conditions) treatable with external glucocorticosteroids: psoriasis, atopic dermatitis, chronic lichen simplex (limited neurodermitis), eczema,

Itchy dermatoses, insect bites, 1st degree burns, sunburns, tinea versicolor, discoid lupus erythematosus.

Active ingredient

Mometasone, [Heparin sodium]

Composition

1 g cream contains:

Active ingredients:

Mometasone furoate – 0.1 mg,

Sodium heparin – 60 IU (0.5 mg with sodium heparin activity 120 IU/mg);

Associates:

Liquid paraffin – 100 mg,

Vaseline – 100 mg,

Propylene glycol – 150 mg,

Stearic acid 50 – 10 mg,

Distilled monoglycerides – 10 mg,

Glycerol – 50 mg,

Macrogol cetostearate – 10 mg,

Poloxamer (emuksol 268) – 5 mg,

Citostearyl alcohol (cetyl alcohol not more than 60 %, stearyl alcohol not less than 40 %) – 25 mg,

Imides – 10 mg.

Imidourea – 2 mg,

Butylhydroxytoluene – 1 mg,

Water – up to 1 g.

How to take, the dosage

Externally.

The cream is applied to the affected areas of the skin in a thin layer once a day.

The duration of treatment is 7-28 days and depends on the nature and severity of the disease.

In case of limited vulgar psoriasis the treatment duration is 21 days.

Interaction

There is no data on the interaction of the drug with other medicines.

Special Instructions

When applied to large areas of skin over an extended period of time, especially when using occlusive dressings, glucocorticosteroids may enter the systemic bloodstream and develop systemic

the effects of glucocorticosteroids. With this in mind, patients should be monitored for signs of suppression of hypothalamic-pituitary-adrenal system function and development of Cushing’s syndrome.

An adrenal function monitoring is recommended at regular intervals during treatment. In case of side effects the treatment should be stopped and symptomatic therapy should be prescribed. If secondary infection has occurred, antimicrobial therapy should be used.

Contact of the drug in the eyes should be avoided.

Propylene glycol contained in the drug may cause irritation at the site of application. In these cases, discontinue use and appropriate treatment should be administered.

Please note that glucocorticosteroids may change the appearance of some skin conditions, which may make it difficult to diagnose. In addition, use of glucocorticosteroids may delay wound healing.

In prolonged therapy with glucocorticosteroids, abrupt discontinuation of therapy can lead to ricochet syndrome, manifesting as dermatitis with intense redness of the skin and a burning sensation.

Therefore, after a long course of treatment, discontinuation of the drug should be done gradually, e.g., by switching to an intermittent regimen before discontinuing it completely.

Impact on driving and operating machinery

It does not affect the ability to drive and operate motor vehicles and other machinery.

Contraindications

• Hypersensitivity to the components of the drug or glucocorticosteroids;
• painful acne, perioral dermatitis;
• bacterial, viral (Herpes simplex, Herpes zoster, chicken pox), fungal skin infection;
• tuberculosis, syphilis;
• postvaccinal reactions;
• pregnancy (treatment of large areas of skin, prolonged treatment);
• breastfeeding period;
• children under 18 years of age.

With caution:

Application to facial and intertriginous skin surfaces, use of occlusive dressings, use on large areas of skin and/or for prolonged periods of time. Long-term therapy with systemic glucocorticosteroids.

.

Side effects

Local reactions: burning, itching, paresthesias, folliculitis, acne, skin atrophy, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin maceration, accession of secondary infection, stretch marks, sweat.

When using external forms of glucocorticosteroids for prolonged periods of time and/or to treat large areas of skin (total application area greater than the patient’s palm area), or with the use of occlusive

The side effects typical of systemic glucocorticosteroids may occur, including adrenal insufficiency and Cushing’s syndrome.

Overdose

Symptoms:

Depression of hypothalamic-pituitary-adrenal system function, including secondary adrenal insufficiency.

Treatment:

Symptomatic, if necessary – correction of electrolyte imbalance, withdrawal of the drug (with long-term therapy – gradual withdrawal).

.